V. Feichtenschlager

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

M. Dimon, A. Daud, P. Leboit, 2013, Proceedings of the National Academy of Sciences.

Clinical melanoma characteristics and survival—a single-center retrospective study between 2000 and 2010

C. Posch, I. Vujic, K. Rappersberger, 2019, Wiener Medizinische Wochenschrift.

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients

C. Posch, M. Sanlorenzo, I. Vujic, 2014, British Journal of Cancer.

Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies

D. Arneson, Adam J. Yen, C. Posch, 2014, Oncotarget.

The long non-coding RNA ‘TRASH’ is essential for cell survival in MAPK-driven melanoma

A. Daud, Y. Kohwi, T. Kohwi-Shigematsu, 2022 .

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment

K. Rappersberger, S. Ortiz-Urda, V. Feichtenschlager, 2023, Oncotarget.

The therapeutically actionable long non-coding RNA ‘T-RECS’ is essential to cancer cells’ survival in NRAS/MAPK-driven melanoma

Y. Kohwi, T. Kohwi-Shigematsu, C. Posch, 2024, Molecular cancer.